- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Whistleblower Claims
Current Investigations
General
Drug Injury
- Actos
- Accutane
- Fosamax
- GranuFlo/NaturaLyte
- Gadolinium
- Ocella, Yasmin, Yaz
- Pradaxa
- Sleeping Pills
- SSRIs
- Topamax
- Tylenol
- Zithromax/Z-pack
- Zocor/Simvastatin
Medical Devices
- Da Vinci Robot
- DePuy Hip Recall
- Mirena
- Stryker Recall
- Stryker Lawsuit
- Transvaginal Mesh
- Zimmer Hip Implant
Product Liability
- Aveeno Lawsuit
- Atlas Roofing Lawsuit
- Avon/Clarins Products
- AZEK Decking
- Chinese Drywall
- Chrysler Lock-Ups
- Demilec Insulation
- Electrolux Lawsuit
- Energy Drink Lawsuit
- Flushmate Systems
- Ford 5.4L Engine
- Ford & Mercury Transmissions
- Ford Mileage Claims
- GAF Decking
- Jeld-Wen Low E
- LP/ABTCO TrimBoard
- Norcold Lawsuit
- Pozzi and Jeld-Wen
- Remington Lawsuit
- TimberTech Decking
- Toyota Power Windows
- Trex Decking Lawsuit
Food
Pending Settlements
FDA Delays Decision on Actos Replacement
Last week, Japan-based Takeda Pharmaceutical Co Ltd, makers of the drug Actos, announced that the FDA will extend its review of the company’s drug alogliptin. Alogliptin, a diabetes medication, was expected to be the successor to Takeda’s top-selling drug Actos. Before Takeda lost its patent protection on Actos, the type-2 diabetes treatment had been linked to an increased risk of bladder cancer in studies. In response, the FDA issued a warning to doctors who prescribed Actos to patients.
Seeger Weiss LLP, a national plaintiffs’ law firm, has been actively investigating the link between Actos and bladder cancer. If you believe you or someone you know developed bladder cancer as a result of taking Actos, the firm’s drug injury practice will review your case for free. Contact them here.
Subscribe to our RSS
